Apatinib as Second or Later-Line Therapy in Extensive SCLC Apatinib as Second or Later-Line Therapy in Extensive SCLC
Could apatinib be considered a safe and effective option for extensive-stage small cell lung cancer patients who fail to respond to first-line chemotherapy?Translational Lung Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Lung Cancer | Small Cell Lung Cancer